Navigation Links
3SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results
Date:8/15/2011

SHENYANG, China, Aug. 15, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the second quarter and first half ended June 30, 2011.

Second Quarter 2011 Financial Highlights:

  • Total net revenues increased by 29.0% over the second quarter of 2010 to RMB136.1 million (US$21.1 million), compared to RMB105.5 million (US$15.6 million) in the second quarter of 2010.
  • Operating income was RMB30.1 million (US$4.7 million), compared to operating income of RMB27.9 million (US$4.1 million) in the second quarter of 2010.
  • Net income was RMB30.4 million (US$4.7 million), compared to net income of RMB25.5 million (US$3.8 million) in the second quarter of 2010.
  • Net income per American Depositary Share ("ADS") on a fully-diluted basis was RMB1.34 (US$0.21) compared to net income per ADS on a fully-diluted basis of RMB1.16 (US$0.17) for the second quarter of 2010.
  • Cash, cash equivalents and time deposits were RMB725.6 million (US$112.3 million, including restricted cash of RMB0.7 million) at June 30, 2011.

  • First Half 2011 Financial Highlights:

  • Total net revenues increased by 26.0% over the first half of 2010 to RMB254.4 million (US$39.4 million), compared to RMB201.9million (US$29.8 million) in the first half of 2010.
  • Operating income was RMB54.3million (US$8.4 million), compared to operating income of RMB56.1 million (US$8.3 million) in the first half of 2010.
  • Net income was RMB52.5 million (US$8.1million), compared to net income of RMB52.2 million (US$7.7 million) in the first half of 2010.
  • Net income per American Depositary Share ("ADS") on a fully-diluted basis was RMB2.34 (US$0.36) compared to net income per ADS on a fully-diluted basis of RMB2.37 (US$0.35) for the first half of 2010.

  • Second Quarter 2011 Business HighlightsOperations

  • EPIAO, the Company's flagship injectable recombinant human erythropoietin (EPO) product, demonstrated strong growth with net revenue in the second quarter of 2011 rising 27.7% to RMB80.2 million (US$12.4 million), compared to RMB62.8 million (US$9.3 million) in the second quarter of 2010. According to IMS Health, second quarter 2011 market share by value increased by 2.2% points, reaching an all-time high of 44.0%, more than the combined market share of the six closest competitors.
  • Net revenues for TPIAO, the Company's novel recombinant human thrombopoietin (TPO) product, increased by 31.7% to RMB42.3 million (US$6.5 million) in the second quarter of 2011, compared to RMB32.1 million (US$4.7 million) in the second quarter of 2010.
  • Net revenues for Iron Sucrose Supplement increased by 39.1% to RMB6.2 million (US$1.0 million) in the second quarter of 2011, compared to RMB4.5 million (US$0.7 million) in the second quarter of 2010.
  • Net export revenues increased by 54.1% to RMB4.5 million (US$0.7 million), accounting for 3.3% of total net revenue in the second quarter of 2011, compared to RMB2.9 million (US$0.4 million), or 2.8% of net revenues in the second quarter of 2010. The increase was partly attributable to continued strong EPIAO sales to Egypt and Thailand. The GMP certification for EPIAO was renewed in Brazil and an application for GMP certification was submitted in Turkey in line with our strategy of seeking product registrations in more developed countries.

  • Events Subsequent to June 30, 2011

  • The Chinese State Food and Drug Administration ("SFDA") approved a 36,000 IU dosage formulation of EPIAO for the treatment of anemia associated with chemotherapy in cancer patients. High-dose EPIAO is the only dosage form of this kind available in China. The 36,000 IU dosage is comparable to the standardized dose used globally for chemotherapy-induced anemia, allowing for less frequent administration than lower dosage forms, which in turn is expected to provide greater convenience for both patients and caregivers.
  • We formed an investment partnership ("3SBio Ventures" or the "Fund") with Taizhou Oriental CMC Limited ("Taizhou Oriental"), the investment arm of Taizhou China Medical City Company ("CMC"). CMC is a Jiangsu province-based national level high-tech industrial park dedicated to life science innovation and is supported directly by the Ministry of Health, Ministry of Science and Technology and the State Food and Drug Administration. The investment partnership will be managed by Taizhou Huan Sheng Investment Management Company Limited ("Huan Sheng"), a wholly-owned subsidiary of 3SBio. Taizhou Oriental and 3SBio have committed RMB50 million and RMB200 million respectively to the Fund. The initial contribution is 20% of the total commitment with the balance to be drawn down as required. 3SBio Ventures will seek investments in the life science sector that support 3SBio's strategic interests. The Fund will have an investment horizon of 8 years with an option to extend.
  • Dr. David Chen has assumed new responsibilities as the managing partner of 3SBio Ventures and has resigned from his position as chief operating officer of 3SBio Inc. Dr. Chen will focus his efforts on seeking strategic investment opportunities for 3SBio Ventures. Dr. Chen's current responsibilities will be allocated among the senior management team while the Company continues to seek opportunities to strengthen its executive team.
  • Dr. Yingfei Wei has resigned from her position as 3SBio's chief scientific officer but will remain engaged in a consulting role to both 3SBio and 3SBio Ventures. Dr. Dongmei Su, chief technology officer of the company, will take on the role of vice president, R&D and will assume Dr. Wei's current responsibilities.

  • Dr. Jing Lou, chief executive officer of 3SBio, commented, "We are pleased with the strong and rising demand for our core products in the dialysis and oncology areas. EPIAO's market share increased by 2.2% points, reaching an all-time high of 44.0%, more than the combined market share of our six closest competitors. The recent approval of high dosage EPIAO reinforces our pioneering role in the treatment of chemotherapy-related anemia in China. As a result of our educational efforts related to TPIAO's recently approved indication for ITP, the medical community is becoming more aware of the benefits for patients suffering from platelet disorders. Our export business also continues to gain momentum with GMP certificate renewal for EPIAO obtained in Brazil, a market with over 90,000 dialysis patients. We are laying the foundation for future growth in our export business with applications pending in Turkey and Malaysia."

    Dr Lou continued, "We are also pleased to announce an investment partnership with Taizhou Oriental CMC Ltd in Taizhou China Medical City, a national level high-tech industrial park dedicated to life science. This platform will facilitate collaboration with China's public health care sector, providing both funding and access to larger scale initiatives and will play a key role in our future pipeline development for 3SBio. I am also pleased that David Chen will assume a new role as managing partner of 3SBio Ventures. We will continue to source innovative products from around the globe and execute our strategy of developing innovative products which address china's unmet medical needs."

    Three Months Ended June 30, 2011 Unaudited Financial ResultsNet revenues. Net revenues increased by 29.0% to RMB136.1 million (US$21.1 million) for the second quarter of 2011 from RMB105.5 million (US$15.6 million) for the same period in 2010. This increase was largely due to continued strong sales of EPIAO and TPIAO which grew by 27.7% and 31.7%, respectively, over the same period in 2010. TPIAO remained 3SBio's second largest revenue contributor in the quarter, accounting for an all-time high of 31.1% of total net revenues. Export sales increased by 54.1% year-on-year to RMB4.5 million (US$0.7 million), and revenues from Iron Sucrose rose 39.1% year-on-year to RMB6.2 million (US$1.0 million).

    Gross profit. As a result of continued sales growth from key products, gross profit for the second quarter of 2011 increased by 27.7% to RMB121.5 million (US$18.8 million) from RMB95.2 million (US$14.0 million) for the same period in 2010. Gross margins declined 1.0% to 89.2% for the second quarter of 2011 from 90.2% for the same period in 2010. The decline was mainly attributable to new plant depreciation and increased material, labor and energy costs.

    Operating expenses. Operating expenses were RMB91.4 million (US$14.1 million) for the second quarter of 2011, representing an increase of 35.9% from RMB67.2 million (US$9.9 million) for the same period in 2010.

  • Research and development ("R&D") costs. R&D costs for the second quarter of 2011 were RMB10.7 million (US$1.7 million), or 7.8% of net revenues, compared to RMB5.7 million (US$0.8 million), or 5.4% of net revenues, for the same period in 2010. The increase in R&D expenses is primarily attributable to clinical trial and testing expenses related to cancer therapeutics developed in collaboration with Ascentage Pharma and NuPIAO, our second generation version of EPIAO.
  • Sales, marketing and distribution expenses. Sales, marketing and distribution expenses for the second quarter of 2011 were RMB65.3 million (US$10.1 million), or 48.0% of net revenues, compared to RMB48.0 million (US$7.1 million), or 45.5% of net revenues, for the same period in 2010. The increase is mainly attributable to expanded sales and marketing activities, including new product launch initiatives for TPIAO for ITP.
  • General and administrative expenses. General and administrative expenses for the second quarter of 2011 were RMB15.4 million (US$2.4 million), or 11.3% of net revenues, compared to RMB13.5 million (US$2.0 million), or 12.8% of net revenues for the same period in 2010.

  • Operating income. Operating income was RMB30.1 million (US$4.7 million) for the second quarter of 2011, a 7.7% increase from operating income of RMB27.9 million (US$4.1 million) for the same period in 2010. Operating margin for the second quarter of 2011 was 22.1%, a 4.4% decline from operating margin of 26.5% for the same period in 2010. The decline in operating margin is primarily due to increased depreciation expenses related to the new plant and increased R&D and sales, marketing and distribution expenses.

    Interest income. Net interest income was RMB5.1 million (US$0.8 million) for the second quarter of 2011, compared to RMB2.7 million (US$0.4 million) for the same period in 2010. The increase is primarily due to the combined effect of increased time deposits and higher interest rates on time deposits.

    Net income. Net income was RMB30.4 million (US$4.7 million) for the second quarter of 2011, a 18.9% increase over net income of RMB25.5 million (US$3.8 million) for the same period in 2010. Net income per ADS on a fully-diluted basis for the second quarter of 2011 increased to RMB1.34 (US$0.21) compared to RMB1.16 (US$0.17) for the same period in 2010. Net margin for the second quarter of 2011 was 22.4%, a 1.8% decrease over net margin of 24.2% for the same period in 2010.

    Six Months Ended June 30, 2011 Unaudited Financial ResultsNet revenues. Net revenues increased by 26.0% to RMB254.4 million (US$39.4 million) for the first half of 2011 from RMB201.9 million (US$29.8 million) for the same period in 2010. This increase was largely due to continued strong sales of EPIAO and TPIAO which grew by 24.1% and 28.8%, respectively, over the same period in 2010. TPIAO remained 3SBio's second largest revenue contributor in the first half, accounting for an all-time high of 31.5% of total net revenues. Export sales increased by 46.2% year-on-year to RMB8.7 million (US$1.4 million), and revenues from Iron Sucrose rose 29.0% year-on-year to RMB11.1 million (US$1.7 million).

    Gross profit. As a result of continued sales growth from key products, gross profit for the first half of 2011 increased by 22.0% to RMB224.4 million (US$34.7 million) from RMB183.9 million (US$27.1 million) for the same period in 2010. Gross margins declined by 2.9% to 88.2% for the first half of 2011 from 91.1% for the same period in 2010. The decline was mainly attributable to new plant depreciation and increased material, labor and energy costs.

    Operating expenses. Operating expenses were RMB170.1 million (US$26.3 million) for the first half of 2011, representing an increase of 33.1% from RMB127.8 million (US$18.8 million) for the same period in 2010.

  • Research and development ("R&D") costs. R&D costs for the first half of 2011 were RMB18.4 million (US$2.9 million), or 7.2% of net revenues, compared to RMB10.4 million (US$1.5 million), or 5.2% of net revenues, for the same period in 2010. The increase in R&D expenses is primarily attributable to clinical trial and testing expenses related to cancer therapeutics developed in collaboration with Ascentage Pharma, NuPIAO, our second generation version of EPIAO and an anti-TNF compound that targets rheumatoid arthritis, psoriasis and other inflammatory disorders.
  • Sales, marketing and distribution expenses. Sales, marketing and distribution expenses for the first half of 2011 were RMB120.7 million (US$18.7 million), or 47.4% of net revenues, compared to RMB90.8 million (US$13.4 million), or 45.0% of net revenues, for the same period in 2010. The increase is mainly attributable to expanded sales and marketing activities, including new product launch initiatives for TPIAO for ITP.
  • General and administrative expenses. General and administrative expenses for the first half of 2011 were RMB31.0 million (US$4.8 million), or 12.2% of net revenues, compared to RMB26.6 million (US$3.9 million), or 13.2% of net revenues for the same period in 2010.

  • Operating income. Operating income was RMB54.3 million (US$8.4 million) for the first half of 2011, a 3.4% decrease from operating income of RMB56.1 million (US$8.3 million) for the same period in 2010. Operating margin for the first half of 2011 was 21.4%, a 6.4% decline from operating margin of 27.8% for the same period in 2010. The decline in operating margin is primarily due to increased depreciation expenses related to the new plant and increased R&D and sales, marketing and distribution expenses.

    Interest income. Net interest income was RMB8.7 million (US$1.4 million) for the first half of 2011, compared to RMB5.8 million (US$0.9 million) for the same period in 2010. The increase is primarily due to the combined effect of increased time deposits and higher interest rates on time deposits.

    Net income. Net income was RMB52.5 million (US$8.1 million) for the first half of 2011, a 0.6% increase over net income of RMB52.2 million (US$7.7 million) for the same period in 2010. Net income per ADS on a fully-diluted basis for the first half of 2011 decreased to RMB2.34 (US$0.36) compared to RMB2.37 (US$0.35) for the same period in 2010. Net margin for the first half of 2011 was 20.7%, a 5.1% decrease over net margin of 25.8% for the same period in 2010.

    Conference Call3SBio's senior management will host a conference call on Tuesday, August 16, 2011 at 5:00am (US Pacific) / 8:00am (US Eastern) / 8:00pm (Beijing) to discuss its unaudited second quarter and first half 2011 results and recent business activity. The conference call may be accessed using the dial-in numbers below:Conference ID:83204042Local dial-in:China landline:

    800-819-0121China mobile:

    400-620-8038Hong Kong:

    852-2475-0994United States:

    718-354-1231 International toll-free dial-in:Hong Kong:

    800930346United States:

    1-866-519-4004United Kingdom:

    080-8234-6646International toll dial-in:65 6723 9381Replay- Conference ID:83204042A telephone replay will be available two hours after the call until August 23, 2011 at:

    International:

    61-2-8235-5000United States:

    1-866-214-5335WebcastA live webcast of the conference will be available on the investor relations section of 3SBio's website at www.3sbio.com and at http://tinyurl.com/3sbio2Q11.

    A replay of the webcast will be available within one hour after the conclusion of the call.

    Statement Regarding Unaudited Financial InformationThe unaudited financial information set forth above is preliminary and subject to adjustments and modifications. The audited financial statements and related notes are to be included in the Company's annual report on Form 20-F for the year ending December 31, 2011. Adjustments and modifications to the financial statements may be identified during the course of the audit work, which could result in significant differences from this preliminary unaudited financial information.

    Currency Convenience TranslationFor the convenience of readers, certain RMB amounts have been translated into US dollars at the rate of RMB6.4635 to US$1.00, the noon buying rate for US dollars in effect on June 30, 2011 as set forth in the H.10 statistical release of the U.S. Federal Reserve Board. A rate of 6.7815 was used for comparative purposes as of June 30, 2010, which was the noon buying rate for US dollars on that date for cable transfers of RMB per US dollar as certified for customs purposes by the Federal Reserve Bank of New York.

    About 3SBio Inc.3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 700 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information.

    Cautionary Statement concerning Forward Looking StatementsCertain statements in the disclosures of 3SBio with respect to  the fiscal year 2011and the second quarter ("Disclosures") that are not purely historical in nature may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Disclosures include the press release, the conference call and any accompanying materials, and any other information issued, released or publicized by 3SBio with respect to the fiscal year 2011 and the second quarter.

    These forward-looking statements address activities, events, conditions, or developments that we currently expect may occur in the future, and include, but may not be limited to, discussions and statements regarding: revenue guidance, business prospects of the Fund, product pricing trends, revenue contribution of new products, tendering process in government procurements, exports prospects, regulatory approval in new markets, business objectives, market size , dialysis growth, product development,  clinical trial progress, regulatory approval process, collaborations, acquisitions and licensing, impact of government policies and regulations, production capacity, capital expense, and future operations and strategies. Forward-looking statements can be identified by such terminology as "believe," "expect," "plans," "strategy," "potential", "prospects," "forecast," "estimate," "project," "anticipate," "aim," "will" or "would", "may" or "might", and words, phrases, expressions, and usages of similar meaning or substance or the negative thereof.

    Forward-looking statements are based on management's current assumptions, beliefs, expectations, and projections, in light of the information currently available, and actual results could differ materially from those implied or expressed by the forward-looking statements. Among the factors that could cause 3SBio's actual results to differ from what 3SBio currently anticipates may include: government policies, actions and measures; evolving healthcare reform at the central government and the provincial government level; regulatory environment and other risks in a new market; the ability of the Fund to raise additional capital; the ability of the Fund to invest successfully, in financial and strategic terms; regulatory compliance risk; the ability of 3SBio or any source it relies on to estimate or forecast accurately; competition from other domestic and foreign pharmaceutical companies; the market growth for pharmaceutical products in China; market acceptance of 3SBio products; hospital or patient demand for our products; the completion and results of 3SBio's ongoing clinical trials; receipt and timing of regulatory approvals for 3SBio's new products and indications; risks associated with collaborations, licensing, and acquisitions; risks in seeking international certification and approvals; 3SBio's ability to expand its production, sales and distribution network and other aspects of its operations; its ability to effectively protect its intellectual property; other changes in the healthcare industry and in the health insurance system in China; and fluctuations in general economic and business conditions in China.

    For additional information on factors identified above and other risk factors, uncertainties and assumptions that may affect 3SBio's business, financial conditions and results of operations, please refer to 3SBio's filings with the Securities and Exchange Commission at www.sec.gov, and, in particular, "Introduction – Cautionary Statement concerning Forward Looking Statements", Item 3.D "Risk Factors", Item 5. "Operating and Financial Review and Prospects", and other applicable discussions in 3SBio's annual report on Form 20-F for the year ended December 31, 2010.

    All the statements in the Disclosures speak as of the date of the initial release, even if subsequently made available on our website or otherwise. 3SBio undertakes no obligation to update or revise these statements after the date of release, whether as a result of new information, subsequent events or otherwise, except as required by law.

    Investor ContactsBo TanChief Financial Officer3SBio Inc.Tel: + 86 24 2581-1820ir@3SBio.com Tom FolinsbeeDirector of Investor Relations3SBio Inc. Tel: + 852 8191-6991ir@3SBio.com 3SBio Inc. Unaudited consolidated balance sheets(expressed in thousands)December 31,2010June 30,2011June 30,2011RMBRMBUS$Assets (unaudited)(unaudited)Current assetsCash and cash equivalents

    153,250106,26316,440Restricted cash

    1,662663103Time deposits with financial institutions

    378,405548,70284,892Accounts receivable, less allowance for doubtful accounts:December 31, 2010 – RMB2,663; June 30, 2011 – RMB2,633(US$407)

    78,500111,55717,260Notes receivable

    55,64629,9254,630Inventories

    21,71820,5523,180Prepaid expenses and other receivables

    39,39021,8193,376Available-for-sale securities

    50,66728,8444,463Prepaid to related parties

    12,0009,0001,392Deferred tax assets

    2,1982,841440Total current assets793,436880,166136,176Time deposits with financial institutions

    120,00070,00010,830Available-for-sale securities

    12,69712,5191,937Investment in  non-consolidated affiliates

    3,8353,854596Property, plant and equipment, net

    199,456199,09630,803Lease prepayments

    8,1888,0111,239Non-current deposits

    1,5559,3121,441Intangible assets, net

    44,29951,4667,963Long term receivables, less allowance for doubtful accounts:  December 31, 2010 - RMB 858; June 30, 2011 - RMB818 (US$127)

    2,5583,411528Deferred tax assets

    37332450Total assets1,186,3971,238,159191,563Liabilities and shareholders' equityCurrent liabilitiesAccounts payable

    5,0304,336671Deferred grant income

    1,37437458Accrued expenses and other payables

    39,55247,5237,354Income tax payable

    1,9866,9361,073Total current liabilities47,94259,1699,156Deferred grant income

    2,4022,216343Total liabilities50,34461,3859,499Shareholders' equityShare capital - ordinary shares US$0.0001 par value, 500,000,000 shares authorized, 152,654,148 and 153,400,192 issued and outstanding as of December 31, 2010 and June 30, 2011, respectively

    12312319Additional paid-in capital

    946,717960,627148,623Accumulated other comprehensive loss

    (89,531)(115,234)(17,829)Retained earnings

    278,744331,25851,251To   Total shareholders' equity1,136,0531,176,774182,064Total liabilities and shareholders' equity1,186,3971,238,159191,5633SBio Inc.Unaudited quarterly consolidated statements of income(expressed in thousands, except per share , per ADS and other share and ADS data)For the Three Months EndedFor the Three Months EndedJune 30, 2010June 30, 2011RMBUS$RMBUS$(unaudited)(unaudited)(unaudited)(unaudited)Net Revenues:EPIAO

    62,797

    9,26080,175

    12,404TPIAO

    32,135

    4,73942,312

    6,546Intefen

    1,236

    1821,365

    211Inleusin

    500

    74762

    118Iron sucrose

    4,459

    6586,204

    960Export

    2,926

    4314,508

    697Others

    1,439

    212806

    125Total net revenues

    105,492

    15,556136,132

    21,061Cost of revenues(10,332)

    (1,524)(14,660)

    (2,268)Gross profit95,160

    14,032121,472

    18,793Operating expensesResearch and development costs

    (5,741)

    (847)(10,686)

    (1,653)Sales, marketing and distribution expenses

    (47,987)

    (7,076)(65,314)

    (10,105)General and administrative expenses

    (13,516)

    (1,993)(15,413)

    (2,385)Total operating expenses

    (67,244)

    (9,916)(91,413)

    (14,143)Operating income 27,916

    4,11630,059

    4,650Interest income

    2,653

    3925,105

    790Grant income

    93

    1493

    14Gain/(loss) from investment in non-consolidated affiliates

    (126)

    (19)526

    81Other income, net

    711

    1051,459

    226Total other income, net3,331

    4927,183

    1,111Income before income tax expense  

    31,247

    4,60837,242

    5,761Income tax expense

    (5,723)

    (844)(6,890)

    (1,066)Net  income25,524

    3,76430,352

    4,695Net income per share:Basic

    0.17

    0.020.20

    0.03Diluted

    0.17

    0.020.19

    0.03Basic weighted average number of shares outstanding

    150,849,065

    150,849,065153,013,696

    153,013,696Diluted weighted average number of shares outstanding

    154,426,639

    154,426,639158,002,003

    158,002,003Net income per ADS:Basic

    1.18

    0.171.39

    0.21Diluted

    1.16

    0.171.34

    0.21Basic weighted average number of ADSs outstanding

    21,549,866

    21,549,86621,859,099

    21,859,099Diluted weighted average number of ADSs outstanding

    22,060,948

    22,060,94822,571,715

    22,571,7153SBio Inc.Unaudited first half consolidated statements of income(expressed in thousands, except per share , per ADS and other share and ADS data)For the Six Months EndedFor the Six Months EndedJune 30, 2010June 30, 2011RMBUS$RMBUS$(unaudited)(unaudited)(unaudited)(unaudited)Net Revenues:EPIAO

    120,009

    17,697148,976

    23,049TPIAO

    62,120

    9,16080,031

    12,382Intefen

    2,573

    3792,570

    398Inleusin

    1,033

    1521,370

    212Iron sucrose

    8,577

    1,26511,061

    1,711Export

    5,982

    8828,746

    1,353Others

    1,574

    2321,613

    250Total net revenues

    201,868

    29,767254,367

    39,355Cost of revenues(17,927)

    (2,644)(29,960)

    (4,635)Gross profit183,941

    27,123224,407

    34,720Operating expensesResearch and development costs

    (10,423)

    (1,537)(18,436)

    (2,852)Sales, marketing and distribution expenses

    (90,803)

    (13,390)(120,674)

    (18,670)General and administrative expenses

    (26,573)

    (3,918)(31,037)

    (4,802)Total operating expenses

    (127,799)

    (18,845)(170,147)

    (26,324)Operating income 56,142

    8,27854,260

    8,396Interest income

    5,795

    8558,727

    1,350Grant income

    187

    281,187

    184Gain/(loss) from investment in non-consolidated affiliates

    (126)

    (19)20

    3Other income, net

    862

    1271,565

    242Total other income, net6,718

    99111,499

    1,779Income before income tax expense  

    62,860

    9,26965,759

    10,175Income tax expense

    (10,685)

    (1,576)(13,245)

    (2,049)Net  income52,175

    7,69352,514

    8,126Net income per share:Basic

    0.35

    0.050.34

    0.05Diluted

    0.34

    0.050.33

    0.05Basic weighted average number of shares outstanding

    150,788,700

    150,788,700152,861,181

    152,861,181Diluted weighted average number of shares outstanding

    153,878,594

    153,878,594157,373,613

    157,373,613Net income per ADS:Basic

    2.42

    0.362.40

    0.37Diluted

    2.37

    0.352.34

    0.36Basic weighted average number of ADSs outstanding

    21,541,243

    21,541,24321,837,312

    21,837,312Diluted weighted average number of ADSs outstanding

    21,982,656

    21,982,65622,481,945

    22,481,945
    '/>"/>

    SOURCE 3SBio Inc.
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. 3SBio Inc. Schedules Unaudited Second Quarter 2011 Results
    2. 3SBio Inc. Announces SFDA Approval of High-Dose EPIAO
    3. 3SBio Announces Conversion of Isotechnika Debenture
    4. 3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results
    5. 3SBio Announces Partial Conversion of Isotechnika Debenture
    6. 3SBio Announces Investor Conference Schedule
    7. 3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
    8. 3SBio Inc. Announces Results of Annual General Meeting
    9. NewCardio Announces Financial Results for Its 2011 Second Quarter
    10. Dehaier Medical Announces Record Second Quarter 2011 Financial Results
    11. Emdeon Announces Support for Electronic Prescribing of Controlled Substances Using the DEA-Allowed Quicker-to-Market Approach
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/12/2016)... SEOUL, South Korea , Feb. 12, 2016 ... today announced they will form a partnership to ... medicine in cancer. The goal of the collaboration ... with Macrogen,s high-throughput Next Generation Sequencing capabilities toward ... Laboratory Improvement Amendments (CLIA) of 1988 by the ...
    (Date:2/12/2016)... Feb. 12 2016  OMS Supply, a large provider ... practitioners, announced today the recent launching of their new ... variety of features that enhance the user experience and ... --> --> ... new company that started in early 2016, they have ...
    (Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
    Breaking Medicine Technology:
    (Date:2/12/2016)... , ... February 12, 2016 , ... A lot has ... 35 years. A president has access to health and wellness resources most Americans could ... world, no single individual has a schedule as frenetic as the U.S. President. ...
    (Date:2/12/2016)... ... February 12, 2016 , ... ... growth in the field of long term care. With that, says Patrick Loughney, ... healthcare professionals in administrative roles in long term care environments. His company, which ...
    (Date:2/12/2016)... Aliso Viejo, CA (PRWEB) , ... February 12, 2016 , ... ... by Pixel Film Studios. The new cartoon style themes are great for showcasing pictures, ... with completely customized scene generators, titles like introductions, lower thirds, transitions and a beautiful ...
    (Date:2/11/2016)... ... February 12, 2016 , ... Fitbody Personal Training offers outdoor training classes ... way to get fit and healthy. Located in Phoenixville, PA, the classes are structured ... designed for horseback riders who want to lose weight and tone up. This class ...
    (Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... (DMPG) will use the action analytics leader’s population health solutions, MDinsight® and ... clinical support to the Atlanta-area healthcare system. Details of the contract were not ...
    Breaking Medicine News(10 mins):